Gordon, Keith

No ORCID on file · 4 papers in corpus
2021
Additional file 1 of Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
·doi:10.6084/m9.figshare.14795093

Additional file 1: Supplemental Table 1. Endometriosis Health Profile-30 at month 3 – pain; Supplemental Table 2. Endometriosis Health Profile-30 at month 3 – control and powerlessness; Supplemental Table 3. Endometriosis Health Profile-30 …

2021
Additional file 1 of Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
·doi:10.6084/m9.figshare.14795093.v1

Additional file 1: Supplemental Table 1. Endometriosis Health Profile-30 at month 3 – pain; Supplemental Table 2. Endometriosis Health Profile-30 at month 3 – control and powerlessness; Supplemental Table 3. Endometriosis Health Profile-30 …

rct 2021
Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
·doi:10.6084/m9.figshare.c.5470895

Abstract Background Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain.…

rct 2021
Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
·doi:10.6084/m9.figshare.c.5470895.v1

Abstract Background Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain.…